Rule 89(5) for Pharma Formulations: The Complete Refund Playbook

A Tier-1 integrated pharma formulator running formulation plants at Ahmedabad in Gujarat, Baddi in Himachal Pradesh, and Sikkim closes its books for October 2025 — the first full tax period under the 56th GST Council rate reset that took effect on 22 September 2025. All Chapter 30 medicaments now sit at a flat 5 percent GST output rate. The plant network’s packaging inputs remain at 18 percent under HSN Chapters 39 and 48. Solvent inputs — hexane, isopropyl alcohol, methanol, toluene and methyl ethyl ketone used in the wet-granulation and API-purification steps — remain at 18 percent under HSN Chapter 27. Active pharmaceutical ingredients sit at 5 percent under HSN Chapter 29 (2941 for antibiotics) or Chapter 30 (3003 for bulk drug mixtures). Excipients — starch, microcrystalline cellulose, dicalcium phosphate, magnesium stearate, lactose — sit at 5 to 12 percent under HSN Chapters 11, 17, 38 and 3505. At an aggregate FY 2026-27 domestic Chapter 30 turnover of the order of Rs 8,500 crore across the three-plant network, the electronic credit ledger accumulates unutilised inverted-duty ITC at a rate that translates to an illustrative monthly refund quantum in the range of Rs 42 to 58 crore per major plant — depending on the API-to-solvent input mix and the Chapter 27 solvent proportion carved out. This is Rule 89(5) inverted duty refund pharma formulations at operating scale, and the discipline that separates a defensible monthly Form GST RFD-01 filing from a deficiency-memo cycle is a per-plant per-tax-period workbook that decomposes Net ITC by input HSN chapter, correctly excludes input services and capital goods from the numerator, and discloses the Notification 09/2022 Chapter 27 solvent carve-out as a distinct line.

Quick reference

The reconciliation in one paragraph

A pharma formulator producing Chapter 30 medicaments — tablets, capsules, syrups, injectables — sells its output at 5 percent GST post the 22 September 2025 rate reset. Its input base is structurally rate-mixed: active pharmaceutical ingredients at 5 percent under Chapter 29 or Chapter 30, packaging at 18 percent under Chapters 39 and 48, solvents at 18 percent under Chapter 27, and excipients at 5 to 12 percent. The weighted average input rate sits materially above 5 percent, so every tax period locks unutilised input tax credit into the electronic credit ledger. Section 54(3) of the CGST Act 2017 permits a refund of that unutilised credit; Rule 89(5) of the CGST Rules 2017, as amended prospectively by Notification 14/2022-Central Tax dated 5 July 2022, gives the formula. Net ITC in the numerator excludes input services and capital goods (a position the Supreme Court confirmed in Union of India v. VKC Footsteps). The refund is filed monthly on Form GST RFD-01 per state GSTIN, with a Statement 1A invoice-level annexure. Notification 09/2022-Central Tax (Rate) dated 13 July 2022 bars Section 54(3) refund on output supplies falling under HSN Chapter 15 or Chapter 27 — the direct legal footprint is on the output side (a Chapter 27 solvent seller cannot claim the refund) but the Chapter 27 solvent input proportion of a Chapter 30 formulator’s Net ITC is nonetheless the reconciliation surface where field-officer scrutiny concentrates. The per-plant per-month refund workbook must decompose Net ITC by input HSN chapter, disclose the Chapter 27 solvent leg transparently, and reconcile the plant’s GSTR-1 output register against the GSTR-2B input register at invoice level.

What the scenario looks like in India

The Indian pharma formulation industry runs a multi-plant footprint that reflects both historical excise-legacy geography and current tax-jurisdiction economics. Baddi in Himachal Pradesh anchors a large slice of national formulation capacity because it was the beneficiary of the erstwhile area-based excise exemption regime up to 2010 — the plants built under that regime remain in operation. Sikkim similarly hosts a concentration of formulation capacity that traces to the Section 80-IE income-tax deduction for units in specified north-eastern and hill states. Gujarat’s Ahmedabad-Vadodara corridor and Halol cluster carry integrated formulation-plus-API capacity built by the Gujarat-headquartered majors. The Telangana-Andhra Pradesh belt — Hyderabad, Bachupally, Bollaram, Vishakhapatnam — anchors a significant share of API and complex-generics capacity feeding both domestic formulation plants and export contract-manufacturing lines. Maharashtra’s Kurkumbh, Ankleshwar in Gujarat, and Verna in Goa complete the geographic spread. Each plant sits under a separate state GSTIN, files its own GSTR-1 and GSTR-3B, and — under Section 54(3) read with Rule 89(5) — files its own Form GST RFD-01 refund claim monthly against the accumulated inverted-duty ITC at that plant’s electronic credit ledger.

Illustrative Tier-1 and Tier-2 integrated pharma formulators operating multi-plant Chapter 30 output networks at the scale relevant to this reconciliation include Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences (the merged entity formerly Cadila Healthcare), Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals and Cadila Pharmaceuticals. Tier-2 speciality and biosimilars formulators with multi-plant footprints include Biocon Biologics, Piramal Pharma, Ipca Laboratories, Ajanta Pharma, Natco Pharma, Laurus Labs, Granules India, Strides Pharma Science, and JB Chemicals & Pharmaceuticals. Divi’s Laboratories and Neuland Laboratories skew to Chapter 29 API output rather than Chapter 30 formulation — their inversion cycles run against a different rate arithmetic but the Rule 89(5) mechanic is common.

For the reconciliation this article walks through, the reference persona is a Tier-1 integrated formulator running three primary formulation plants — Ahmedabad, Baddi, and Sikkim — at an aggregate FY 2026-27 domestic Chapter 30 turnover of the order of Rs 8,500 crore, with each plant sized in the Rs 2,000 to 3,500 crore annual turnover band. The three-plant network sits under three distinct state GSTINs (Gujarat, Himachal Pradesh, Sikkim) and files three parallel monthly Form GST RFD-01 claims. The finance team’s design objective is a template Rule 89(5) refund workbook that runs consistently across all three plants — so the treasury projection, the deficiency-memo response cycle, and the year-end refund reconciliation against the aggregate accumulated inverted-duty ITC all draw from a common base.

The regulatory overlay — Section 54(3), Rule 89(5), and the twin notifications of July 2022

Three anchors govern the pharma formulator’s inverted-duty refund cycle post the 22 September 2025 rate reset. Two are procedural — the CGST Act 2017 and Rules 2017 as amended in July 2022 — and one is contextual: the 56th GST Council decision itself, which is the reason inversion deepened in the first place.

Section 54(3) of the Central Goods and Services Tax Act 2017 permits a registered person to claim refund of unutilised input tax credit where the credit has accumulated on account of the rate of tax on inputs being higher than the rate of tax on output supplies — the inverted duty structure. The first proviso to Section 54(3) empowers the government to notify supplies against which refund of unutilised ITC shall not be allowed. The Supreme Court in Union of India v. VKC Footsteps India Pvt Ltd (2021) 10 SCC 674 upheld the statutory scheme and confirmed that the refund is confined to unutilised credit on inputs — input services and capital goods stand excluded from the Net ITC base. The judgment was the definitive constitutional-validity anchor and remains the reference point in every refund-claim scrutiny.

Rule 89(5) of the Central Goods and Services Tax Rules 2017 gives the operational formula. Maximum Refund Amount = (Turnover of inverted-rated supply of goods and services × Net ITC / Adjusted Total Turnover) minus (Tax payable on such inverted-rated supply × Net ITC / ITC availed on inputs and input services). Notification 14/2022-Central Tax dated 5 July 2022 amended the rule prospectively — refund applications filed on or after 5 July 2022 apply the amended formula; earlier applications use the pre-amendment version. Two changes carry the practical impact for a Chapter 30 formulator. First, Net ITC in the numerator was expressly codified as excluding input services and capital goods — settling the interpretive dispute in favour of the VKC Footsteps position. Second, the second limb of the formula — the subtraction term for tax payable on the inverted-rated supply — was rebalanced by applying the ratio of Net ITC over the sum of ITC availed on inputs and input services, tightening the maximum refund quantum for taxpayers with a heavy internal input-services ITC share.

Notification 09/2022-Central Tax (Rate) dated 13 July 2022, effective 18 July 2022, invokes clause (ii) of the first proviso to Section 54(3) and bars Section 54(3) refund on output supplies falling under HSN Chapter 15 (animal or vegetable fats and edible oils) or HSN Chapter 27 (mineral fuels, mineral oils, products of distillation — the chapter that houses hexane, isopropyl alcohol, methanol, toluene and methyl ethyl ketone). The direct legal footprint of the notification sits on the output side — a manufacturer whose output is Chapter 27 solvent cannot claim inverted-duty refund on its own inversion cycle, regardless of its input rates. For a Chapter 30 formulator the output is 5 percent Chapter 30 medicaments; the refund is not directly barred by the notification. The reconciliation surface — where the notification’s practical footprint sits — is the Chapter 27 solvent proportion of the formulator’s Net ITC. Some proper officers apply an interpretive carve-out at scrutiny, treating the solvent leg of Net ITC as a disclosure-and-defence line rather than an automatic inclusion. The reconciliation discipline is to hold the Chapter 27 solvent input register as a distinct line in the Net ITC composition workbook, so the refund claim discloses the composition transparently and any officer challenge is answered with the invoice-level solvent register rather than with an aggregate ITC pool.

The 56th GST Council meeting held on 3 September 2025, with recommendations effective 22 September 2025, is the reason the inversion deepened. The rate reset moved all Chapter 30 formulations to a flat 5 percent, moved medical devices under HSN 9018 to 9022 from 18 percent to 5 percent, and moved a specified schedule of life-saving drugs for cancer, HIV, tuberculosis and rare diseases to nil rate. The Council’s own FAQ set — including Q10 (on the transition treatment), Q25 (on medical devices) and Q51 (on the schedule of nil-rated life-saving drugs) — explicitly acknowledged that the reset deepens inversion for Chapter 30 formulators and pledged expedited processing of Section 54(3) refunds under the Rule 89(5) framework.

A worked example — an illustrative three-plant formulator at monthly close

Illustrative — the following figures represent the operating pattern of a Tier-1 pharma formulator running a three-plant network at the scale that Indian large-cap listed formulators operate. Public disclosures do not reveal per-plant per-month inverted-duty refund quantum in the granularity below; cross-verify against your own plant’s GSTR-1 and GSTR-2B extracts before action.

The formulator’s Baddi plant closes October 2025 — the first full tax period under the 22 September 2025 rate reset — with the following outward and inward supply position, converted to Rs crore for the tax period:

For the Notification 14/2022 amended Rule 89(5) formula, Net ITC is Rs 17.46 crore (the eligible-input ITC only — input services and capital-goods ITC are excluded from the numerator even though both sit as ordinary ITC in the electronic credit ledger). Turnover of inverted-rated supply is Rs 302.0 crore. Adjusted Total Turnover for the plant for the tax period is Rs 302.0 crore (the plant’s outward supplies are entirely Chapter 30 inverted-rated). Tax payable on the inverted-rated supply is Rs 15.10 crore. ITC availed on inputs and input services (the denominator of the second-limb ratio) is Rs 17.46 + Rs 2.07 = Rs 19.53 crore.

Applying the amended Rule 89(5) formula: first limb = (302.0 × 17.46 / 302.0) = Rs 17.46 crore; second limb = (15.10 × 17.46 / 19.53) = Rs 13.50 crore; maximum refund = 17.46 − 13.50 = Rs 3.96 crore for the Baddi plant for October 2025 alone. Across the three-plant network at the illustrative Rs 42 to 58 crore per major plant monthly refund range that the persona describes, the aggregate accumulated refund position for the network sits at approximately Rs 120 to 170 crore per month — before any Chapter 27 solvent carve-out adjustment that a proper officer might apply at scrutiny.

The Chapter 27 solvent proportion of Net ITC — Rs 3.24 crore of Rs 17.46 crore, or 18.6 percent for the Baddi tax period above — is disclosed as a distinct line in the Statement 1A invoice-level annexure. If a proper officer applies an interpretive carve-out and disallows the Chapter 27 solvent leg, the maximum refund adjusts down to (302.0 × 14.22 / 302.0) − (15.10 × 14.22 / 19.53) = 14.22 − 10.99 = Rs 3.23 crore — a Rs 0.73 crore reduction against the base-case Rs 3.96 crore claim. The reconciliation discipline is to hold both computations in the workbook and be prepared to defend the Chapter 27 solvent inclusion at scrutiny.

The Ahmedabad plant runs a similar composition with a higher API leg (Chapter 29 backward integration) and a lower solvent proportion; the Sikkim plant runs a lower packaging leg (regional cost structure) but a similar solvent proportion. Each plant’s Form GST RFD-01 is filed against its own state GSTIN on the GST portal; the provisional refund of up to 90 percent is granted in Form GST RFD-04 within seven days; the final sanction follows in Form GST RFD-06 after scrutiny.

Common reconciliation breakages

Five breakages recur across Indian Chapter 30 formulators running the Rule 89(5) monthly refund cycle post the 22 September 2025 rate reset, and each maps to a specific control failure that a deficiency memo in Form GST RFD-03 will surface.

• Input-services ITC bleed into the Net ITC numerator. The most common cause of a partial refund rejection is inclusion of input-services ITC — freight on API and packaging inbound, external analytical laboratory services, engineering consulting, plant maintenance contracts — in the Net ITC base. The exclusion was codified in the Notification 14/2022 amendment and settled at the Supreme Court in VKC Footsteps. Formulators that treat the entire GSTR-2B ITC pool as Net ITC without separating input-service line items produce an over-stated refund claim that the proper officer rejects with a Form GST RFD-03 deficiency memo. Reconciliation discipline: the input-services ledger must be extracted from GSTR-2B at source and held in a separate accounting bucket, with the Net ITC formula drawing only from the goods-input register.

• Capital-goods ITC bleed into Net ITC. Similar failure mode with a different attack vector — capital-goods ITC on reactors, granulators, compression machines, blister packaging lines, HVAC additions, cold-chain infrastructure is not eligible for Section 54(3) inverted-duty refund and does not enter Net ITC. The standing refund mechanism for capital-goods ITC sits under separate provisions, not Rule 89(5). Formulators that include capital-goods ITC in the numerator produce a rejection at scrutiny and a partial reversal against the electronic credit ledger.

• Chapter 27 solvent composition undisclosed. The refund claim itself is not directly barred by Notification 09/2022 for a Chapter 30 formulator, but the Chapter 27 solvent proportion of Net ITC is the surface where field-officer scrutiny concentrates. A refund claim that presents Net ITC as an aggregate without disclosing the solvent leg invites a proper officer challenge on the interpretive carve-out, and forces the formulator to reconstruct the invoice-level solvent register under time pressure to defend the claim. Reconciliation discipline: the Statement 1A annexure discloses the Chapter 27 solvent line explicitly, and the workbook holds both the base-case computation (solvent included) and the carved-out computation (solvent excluded) so the response to any scrutiny query is a one-click swap.

• Cross-period straddle-invoice mis-attribution. The 22 September 2025 rate cutover created a specific straddle window — invoices dated before 22 September for goods dispatched pre-cutover but received (and ITC availed) post-cutover carry the pre-reset input rate but feed the post-reset Net ITC. Under Section 15 of the CGST Act 2017 the time-of-supply rule for goods generally follows the invoice date. Formulators that assign the straddle-invoice ITC to the wrong tax period distort the September 2025 and October 2025 Rule 89(5) claims, either over- or under-stating Net ITC for the respective months. The Pharma Wave 1 sibling article on the straddle invoice reconciliation walks the cutover mechanic in detail; the Rule 89(5) implication is that the workbook must run a cutover reconciliation between the invoice date and the ITC-availment date for the September and October tax periods.

• Adjusted Total Turnover base miscount. Adjusted Total Turnover in the Rule 89(5) denominator excludes turnover from supplies for which refund is claimed under other subsections of Section 54 and excludes exempt turnover. Formulators with a mixed portfolio — including nil-rated life-saving drugs under the 22 September 2025 schedule, or export supplies claiming refund under Section 54(1) with Letter of Undertaking — that fold the entire aggregate turnover into Adjusted Total Turnover mis-scale the ratio and produce an incorrect maximum refund. Reconciliation discipline: the Adjusted Total Turnover base is built as an explicit register keyed to supply type — inverted-rated, exempt, nil-rated, zero-rated with LUT, zero-rated with tax payment — and only the correct legs feed the Rule 89(5) denominator.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the plant-level GSTR-1 outward supply register, the GSTR-2B auto-populated ITC statement, and the plant’s own accounting ledger — and produces a Rule 89(5) refund workbook per plant per tax period that decomposes Net ITC by input HSN chapter, separates the input-services and capital-goods ledgers from the goods-input Net ITC base, applies the Notification 14/2022 amended formula, generates the Statement 1A invoice-level annexure, and drafts the Form GST RFD-01 filing base for portal submission. The platform holds both the base-case computation and the Chapter 27 solvent carve-out computation so the response to any deficiency-memo query is a one-click swap. The straddle-invoice cutover between September and October 2025 tax periods is handled by an invoice-date-versus-availment-date reconciliation that assigns the pre-22-September ITC to the correct tax period. Match rate improvement of 51 to 88 percent on the plant-level GSTR-2B to accounting ITC reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 pharma formulator running a multi-plant Chapter 30 network rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The Chapter 30 formulator’s Rule 89(5) refund cycle documented in this article sits alongside three Wave 1 pharma companions that unpack the operating detail. The pharma inventory GST rate switch on 22 September 2025 reconciliation walkthrough covers the cutover accounting for closing inventory held at the reset date and the straddle-invoice treatment. The GST Council FAQ Q10, Q25 and Q51 pharma clarifications reading guide is the plain-language reference to the specific FAQ answers that finance teams cite in refund claim covering letters. The medical device HSN 9018 to 9022 18 to 5 percent rate change walkthrough covers the parallel inversion cycle that HSN Chapter 90 medical device manufacturers now run against their own 18 percent input base.

The Rule 89(5) mechanic is common across inverted-duty industries. For the dairy sector, where 5 percent packaged milk output against 18 percent packaging input creates a structurally similar inversion, the dairy inverted-duty refund under Rule 89(5) post GST 2.0 walkthrough is the cross-cluster anchor. For the edible oil sector, where Notification 09/2022 directly blocks the refund on the OUTPUT side under HSN Chapter 15 — the same notification whose Chapter 27 leg touches pharma solvent inputs — read the edible oil Chapter 15 inverted-duty refund blocked under Notification 09/2022 walkthrough for the direct-block mechanic.

The methodology framework for building the per-plant per-tax-period reconciliation workbook — mapping every input HSN chapter to a distinct reconciliation surface, holding both base-case and defence-case computations, and building the deficiency-memo response cycle into the standing close process — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The GSTR-2B ITC reconciliation failure-mode reference — feeding directly into the Net ITC composition step of the Rule 89(5) workbook — sits at GSTR-2B ITC reconciliation failure modes. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 54(3) refund workflow.

The five FAQs below address the operational questions Indian pharma indirect-tax leads and formulation-plant controllers ask most often when building a standing monthly Rule 89(5) refund cycle post the 22 September 2025 GST rate reset.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 13 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024